Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients

Détails

Demande d'une copieDemande d'une copie
ID Serval
serval:BIB_0B94F1482735
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Production externe
Titre
Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients
Périodique
AIDS
Auteur⸱e⸱s
Delaugerre C., Mathez D., Peytavin G., Berthe H., Long K., Galperine T., de Truchis P.
ISSN
0269-9370 (Print)
ISSN-L
0269-9370
Statut éditorial
Publié
Date de publication
2007
Volume
21
Numéro
9
Pages
1210-3
Langue
anglais
Notes
Delaugerre, Constance
Mathez, Dominique
Peytavin, Gilles
Berthe, Huguette
Long, Kivan
Galperine, Tatiana
de Truchis, Pierre
eng
England
2007/05/16
AIDS. 2007 May 31;21(9):1210-3. doi: 10.1097/QAD.0b013e32810fd744.
Résumé
In highly experienced HIV-1-infected patients, a ritonavir-boosted darunavir-containing regimen was associated with dramatic immunological and virological efficacy. Patients harbouring viruses with amprenavir-specific resistance profiles, such as I50V or V32I + I47V, failed on a darunavir/ritonavir-containing regimen. These key amprenavir mutations were also selected at the time of failure, suggesting their impact on darunavir efficacy.
Mots-clé
CD4 Lymphocyte Count, Carbamates/*therapeutic use, Darunavir, Drug Resistance, Viral/genetics, Drug Therapy, Combination, Furans, HIV Infections/*drug therapy/genetics/virology, HIV Protease Inhibitors/*therapeutic use, HIV-1/*genetics, Humans, Reverse Transcriptase Inhibitors/therapeutic use, Risk Factors, Ritonavir/therapeutic use, Sulfonamides/*therapeutic use, Treatment Failure, Viral Load
DOI
10.1097/QAD.0b013e32810fd744
Pubmed
17502734
Création de la notice
30/01/2023 12:16
Dernière modification de la notice
31/01/2023 7:55
Données d'usage